Tagrisso TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: osimertinib
Brand name
(ARTG)
: TAGRISSO osimertinib 80 mg (as osimertinib mesilate) tablet blister packDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
TAGRISSO as monotherapy is indicated: as adjuvant therapy after tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have activating epidermal growth factor receptor (EGFR) mutations, as detected by a validated test. for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have activating EGFR mutations, as detected by a validated test. for the treatment of patients with locally advanced or metastatic NSCLC that is EGFR T790M mutation-positive, as detected by a validated test. TAGRISSO is indicated in combination with: pemetrexed and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- Oval, biconvex, beige, film-coated tablets approximately 7.25 x 14.5 mm. The tablets are debossed with AZ 80 on one side and plain on the reverse
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Protect from direct sunlight
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 30 pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient osimertinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
